Literature DB >> 9924172

Association of Killip class on admission and left ventricular dilatation after myocardial infarction: a closer look into an old clinical classification.

A N Nesković1, P Otasević, M Bojić, A D Popović.   

Abstract

BACKGROUND: Early identification of patients in whom left ventricular dilatation is likely to occur may have important therapeutic implications. Thus the purpose of this study was to evaluate the relation between Killip class on admission and subsequent left ventricular dilatation after acute myocardial infarction. METHODS AND
RESULTS: We serially evaluated 129 consecutive patients by two-dimensional and Doppler echocardiography on days 1, 2, 3, and 7, at 3 and 6 weeks, and at 3, 6, and 12 months after infarction. Killip class on admission >1 was found in 29 of 129 (22.5%) patients, and they had significantly higher end-systolic and end-diastolic volume indexes and wall motion score index from day 1 onward compared with patients with Killip class 1, whereas ejection fraction was lower during the follow-up period in these patients. Patients with Killip class >1 showed the progressive increase of end-diastolic (68.2 +/- 2.99 to 88.0 +/- 7.55 ml/m2, p = 0.001) and end-systolic volume indexes (43.9 +/- 2.67 to 56.3 +/- 6. 18 ml/m2, p = 0.004) during the follow-up period, whereas ejection fraction and wall motion score index remained unchanged. In patients with Killip class 1, end-systolic volume index did not change (30.8 +/- 1.06 to 33.8 +/- 2.15 ml/m2, p = 0.064), ejection fraction increased (49.3% +/- 0.99% to 51.8% +/- 1.17%, p = 0.027), and wall motion score index decreased (1.50 +/- 0.03 to 1.35 +/- 0.04, p < 0. 001). End-systolic volume index was the major independent correlate of Killip class, followed by history of diabetes and peak creatine kinase level. No association was found between Doppler indexes of diastolic filling and Killip class on admission.
CONCLUSIONS: Killip class >1 on admission is associated with both acute and long-term left ventricular dilatation. On the other hand, Killip class 1 is associated with favorable left ventricular functional indices, and it appears that left ventricular function in these patients may improve over time. Initial end-systolic volume index but not ejection fraction is the major correlate of Killip class.

Entities:  

Mesh:

Year:  1999        PMID: 9924172     DOI: 10.1053/hj.1999.v137.89744

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  4 in total

1.  Comparison between the Outcomes of Using Biodegradable-Polymer Drug-Eluting Stents and Those of Using Durable-Polymer Drug-Eluting Stents in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention.

Authors:  Abd-Allah Y Fawzy; Mahmoud M Kenawi; Ahmed Abd El Aziz; Ayman N Moharam; Ibrahim M Attia
Journal:  Open Access Maced J Med Sci       Date:  2019-05-14

2.  Season and myocardial injury in patients with ST-segment elevation myocardial infarction: A cardiac magnetic resonance imaging study.

Authors:  Ik Hyun Park; Woo Jin Jang; Hyun Kyu Cho; Ju Hyeon Oh; Woo Jung Chun; Yong Hwan Park; Mirae Lee; Young Bin Song; Joo-Yong Hahn; Seung-Hyuk Choi; Sang-Chol Lee; Hyeon-Cheol Gwon; Yeon Hyeon Choe
Journal:  PLoS One       Date:  2019-02-08       Impact factor: 3.240

3.  The Value of Different Short-Term Risk Scoring Models in Predicting Long-Term Death of Acute Myocardial Infarction.

Authors:  Bosen Yang; Lin Bai; Yike Zhang; Yiheng Cheng; Chunyan Zhao; Baotao Huang; Mao Chen
Journal:  J Clin Med       Date:  2022-08-28       Impact factor: 4.964

4.  Clinical Significance of Postinfarct Fever in ST-Segment Elevation Myocardial Infarction: A Cardiac Magnetic Resonance Imaging Study.

Authors:  Woo Jin Jang; Jeong Hoon Yang; Young Bin Song; Woo Jung Chun; Ju Hyeon Oh; Yong Hwan Park; Mi Rae Lee; Jin Kyung Hwang; Ji-Won Hwang; Joo-Yong Hahn; Seung-Hyuk Choi; Sang-Chol Lee; Yeon Hyeon Choe; Hyeon-Cheol Gwon
Journal:  J Am Heart Assoc       Date:  2017-04-24       Impact factor: 5.501

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.